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Objectives: To investigate the trajectory in glycemic control following episodes of severe 
hypoglycemia (SH) among children and adolescents with type 1 diabetes (T1D).  
 
Methods: A Danish national population-based study comprising data from 2008-17. SH was 
defined according to the 2014 ISPAD guidelines. A mixed model was applied with HbA1c as 
outcome and SH episodes and time since first episode as explanatory variables. Data were adjusted 
for age, gender and diabetes duration.  
 
Results: A total of 4,244 children (51.6% boys) with 18,793 annual outpatient visits were included. 
Mean (SD) age at diabetes onset was 9.0 (4.1) years. Median diabetes duration at inclusion in the 
study was 1.2 (Q1=0.9, Q3=3.0) years, and median diabetes duration at last visit was 5.0 (Q1=2.7, 
Q3=8.1) years. A total of 506 children experienced at least one episode of SH during the nine-year 
follow-up; 294 children experienced one episode, 115 two episodes and 97 three or more episodes 
of SH. 
HbA1c increased with episodes of SH and in the years following the first episode. The glycemic 
trajectory peaked 2-3 years after an SH episode. The accumulated deterioration in glycemic control 
was in the range of 5% in patients with two or more episodes equivalent to an increase in HbA1c of 
4 mmol/mol (HbA1c ~ 0,4%).  
 
Conclusion: Severe hypoglycemia was followed by a progressive and lasting increase in HbA1c 
among Danish children and adolescents with T1D. Thus, in addition to the known risk of new 
episodes of hypoglycemia and cognitive impairment, SH contributes to long-term diabetes 
complications.  
 


















Target hemoglobin A1c (HbA1c) for glycemic control in children and adolescents with type 1 
diabetes (T1D) is the lowest achievable HbA1c without undue exposure to severe hypoglycemia 




The Diabetes Control and Complications Trial (DCCT) showed that an improvement in glycemic 
control was achieved at the expense of an increase in SH
2
. However, improved glycemic control has 
become a minor risk factor for SH. Thus, the frequency of SH decreased in the period 2004-2012 
compared with the period 1995-2003, which paralleled increasing use of modern diabetes 
technology such as insulin analogs, insulin pumps and glucose sensors
3
.  
Recently,  two comprehensive international studies  in children and adolescents with T1D from the 
population-based German/Austrian registry and the U.S. in the period 2011-12
4
, and from the 
Scandinavian countries in the period 2008-12, respectively
5
, did not find any association between 
HbA1c and SH. 
Though the risk of SH is decreasing, it is still a rather frequent acute complication. Data from the 
Danish Childhood Diabetes Database (DanDiabKids) showed an incidence of 7.6 per 100 person-
years in children below the age of 17 in the period 2008-2013
6
. This is in agreement with results in 
a Scandinavian study comprising children and adolescents reporting an SH incidence of 6.0 per 100 
person-years in the period 2008-12
5
. Although the risk of SH is decreasing and not specifically 
associated to low HbA1c, children with fear of hypoglycemia often have elevated HbA1c and many 
caregivers still connect SH with low HbA1c and prefer a less tight metabolic control. Fear of 
hypoglycemia is thus a major psychological burden for patients and families in the 
pediatric/adolescent setting 
7,8
. In some families, fear of hypoglycemia becomes a barrier in the 
everyday life for children and adolescents. Due to the glucose-lowering effect of physical activity, 
participation in social events and sports  may be avoided potentially impacting on quality of life and 




One or more episodes of SH may have implications on lifestyle and/or diabetes-regulatory behavior 
potentially impacting on glycemic control and risk of long-term diabetes complications. The aim of 
this study was to describe the trajectory in HbA1c after episodes of SH among children and 




Data  were collected as previously described
6
 with yearly registrations in the DanDiabKids from 
diabetes onset until the age of 18
10
.  All Danish children and adolescents with newly diagnosed T1D 
according to the WHO criteria
11
 were included in the DanDiabKids. The register has a data 
completeness concerning incident cases of 99 %
10
 and includes data on age, gender, ethnicity, 
diabetes duration, self-monitored blood glucose (SMBG),  treatment modality (insulin pen/pump), 










insulin type, HbA1c (IFCC) and anthropometric measures. Completeness of annual registrations of 





In the period 2008-17, the DanDiabKids comprised a total of 5,538 children and adolescents below 
18 years of age. All participants with T1D and diabetes duration exceeding six months were 
included in the study. Participants with missing data for SH and/or HbA1c for a period of more than 
18 months were excluded from subsequent analysis, resulting in analysis of 4,244 children and 
adolescents (51.6 % boys) with a total of 18,793 annual outpatient visits.  
 
Definition of variables 
Severe hypoglycemia was defined according to the ISPAD 2014 guidelines as a hypoglycemic 
episode leading to loss of consciousness and/or seizures requiring parental assistance
13
. Severe 
hypoglycemia was registered yearly as a numeric variable.   
HbA1c was measured annually at the central national Diabetes Control and Complications Trial 
(DCCT) standardized laboratory at Herlev Hospital, Copenhagen, using a high-pressure liquid 
chromatographic method (Tosoh Bioscience, South San Francisco, CA, USA). The HbA1c values 
were validated twice monthly by the European Reference Laboratory and aligned with DCCT 
values. HbA1c values were reported according to the International Federation of Clinical Chemistry 
standard (IFCC) in mmol/mol. The reported SH associated absolute changes in HbA1c are reported 
in both IFCC (mmol/mol) and National Glycohemoglobin Standardization Program (NSGP) (%) 
units.  
 
Statistics   
Descriptive characteristics are reported as mean (standard deviation) or percentage of total. When 
data are aggregated across all recorded visits, such that most patients contribute with more than one 
visit, only means or percentages are provided (Table 1). Skewed data distributions are presented as 
medians and interquartile ranges (Q1;Q3). A p-value of < 0.05 was considered statistically 
significant. 
Data were analyzed using a mixed-effects model with log-transformed HbA1c as outcome and a 
random intercept for patients and a random effect of diabetes duration. The cumulative number of 
severe hypoglycemic events (0, 1, 2, 3, 4, >4 events) and time since last SH episode (1: since last 
visit, 2: between two previous visits, 3: more than two visits ago) were included as explanatory 
variables. “Time since last SH episode” allows us to test whether the effect of an SH episode is 
immediate or evolves over time. The ‘combined effect’ covers that there is a significant immediate 
effect and in addition to that a significant effect of time. The primary analyses were adjusted for age 
(≤6, 6-12, >12 years), gender and diabetes duration (years, modeled with a natural spline).  This 
model was used to predict the expected mean HbA1c for given values of covariates.  
 










Additional analyses were adjusted for treatment modality (1: MDI with human insulin, 2: MDI with 
insulin analogs, 3: insulin pump (analogs)) and frequency of SMBG (1: ≤ 2, 2: 3-5, 3: 6-9, 4: >10 
times / day), 5: continuous glucose monitoring (CGM)). 
Participants diagnosed with T1D prior to 2008 were included in the study with the available history 
of SH. Participants lacking information on previous SH were included as having had no prior 
episodes of SH (n=278). A sensitivity analysis was performed assuming one previous episode of 
SH; this did not alter the impact of SH on the reported HbA1c.  
Results  
At T1D onset, the mean age (SD) was 9.0 (4.1) years. At inclusion in the study, median diabetes 
duration (Q1;Q3)  was 1.2 (0.9; 3.0) years; 92.3% of the included were of Danish ethnicity. The 
median follow-up time was 2.9 (1.0;5.1) years and the median diabetes duration at last visit was 5.0 
(2.7;8.1) years. A total of 506 patients experienced one or more episode of SH; 294 patients had one 
episode, 115 patients had two episodes, 55 patients had three episodes, 15 patients had four 
episodes and 27 patients had more than four episodes of SH during the observation period. 
Characteristics of the participants stratified by number of previous SH episodes are shown in Table 
1. In total, the 4,244 participants had 18,793 outpatient visits. Use of insulin pump was the most 
common treatment modality across all SH groups. Neither the treatment modalities in the four SH 
groups, nor frequency of SMBG or CGM use were statistically different in the four SH groups.   
Effect of SH episodes: Episodes of SH were associated with a progressively increasing HbA1c at 
first outpatient visit 0-12 months post SH (Table 2). When adjusting for age, gender and diabetes 
duration; the HbA1c in patients with one SH episode was 1.1% (CI= (0.0;2.6, p=0.02)) higher than 
in patients with no previous episodes. For patients with two SH episodes, the estimated increase 
was 3.3% (CI=1.3;5.6, p<0.01). For an average HbA1c of 64 mmol/mol (HbA1c (NSGP) of 8%) 
this SH-associated change represents an increase in HbA1c in the range of 2.1 mmol/mol 
(IFCC)(CI:0,05;3.6 mmol/mol) corresponding to  approximately 0.26% (NGSP). 
 
Effect of time: At the following visits, the trajectory of HbA1c showed a characteristic pattern, as 
illustrated in figure 1 which shows the predicted six-year trajectories in HbA1c for three 
hypothetical patients with diabetes onset at the age of 6 years, who only differ with respect to the 
occurrence of SH. Patient 1: No SH episodes; Patient 2: 1 SH episode in year 2; Patient 3: 2 SH 
episodes in year 1 and 4. In addition to the immediate adverse effect of experiencing an SH (1.1% at 
the first outpatient visit after the first SH, Figure 1, Patient 1 vs Patient 2), no significant further 
worsening of glycemic control was seen between visits 1 and 2 (12-24 months post SH) (0.8% (CI= 
(-0.5%, 2.0%), p=0.24), but at visit 3 (24-36 months post SH), HbA1c levels were significantly 
higher, about 2% (CI= (0.7%, 3.4%), p=0.003). This time-dependent worsening of glycemic control 
followed the first episode of SH only. Thus, there was no evidence of an additional time-dependent 
increase after later events. 
 










The combined effects of immediate worsening after SH episodes and further increase in HbA1c 
with time since first SH translates into an accumulated and lasting increase in HbA1c of e.g. ~5% 
for patients with two SH episodes or more. For an average HbA1c of 64 mmol/mol (HbA1c 
(NSGP) of 8%) this change represents an increase in HbA1c in the range of 3.2 mmol/mol (IFCC) 
corresponding to approximately 0.4% (NGSP).    
Adjusting for treatment modality and frequency of SMBG or CGM use did not change the 
association between SH and HbA1c, but effect sizes were slightly attenuated (results not shown). 
 
Discussion 
This population-based register study among Danish children and adolescents with T1DM is the first 
to describe the trajectory of glycemic control following episodes of SH. We observed that SH 
episodes were followed by progressive glycemic deterioration; thus, multiple episodes were 
associated with a further increase in HbA1c. Additionally, we noticed that the glycemic 
deterioration following the first episode of SH worsened over time. At the third visit (24-36 
months) after the first episode, HbA1c had increased with approximately 2% on top of the 
immediate impact of the episode. The accumulated and lasting deterioration in glycemic control for 
patients with two SH episodes or more was approximately 5%, equivalent to a rise in HbA1c of 3-4 
mmol/mol depending on the initial level. This change is clinically relevant due to the increased risk 
of later complications, as data from the DCCT study revealed that a reduction in HbA1c of about 3 




Over the past decade, diabetes treatment technology has moved from injection therapy with human 
insulin (neutral protamine Hagedorn (NPH)) towards frequent use of insulin analogs (Detemir and 
Glargine) and/or insulin pumps, and from few SMBG to more frequent SMBG or CGM. Some 




 and frequent 
glucose monitoring
6
 on the risk of SH; others have failed to confirm the positive effect of insulin 
analogs
18
 and insulin pumps
19
 on the SH risk. We observed that several patients with SH changed 
treatment modality from insulin pen to insulin pump. However, in accordance with other studies
20
, 
we observed a general trend among children and adolescents towards treatment with insulin analogs 
and/or insulin pumps during the study period
12
. Supplementary analyses were performed to adjust 
our findings for a potential effect of treatment modality and frequency of SMBG or CGM. These 
adjustments did not significantly change the overall interpretation of SH as a risk factor for 
glycemic deterioration. 
CGM use was low in the present study compared to clinical pediatric practice of today in Denmark. 
Studies have reported reduced fear of hypoglycemia
21
 and improved glycemic control in children 
and adolescents using CGM
22
. Future studies are needed to investigate if CGM use may also 
prevent the deteriorating effect of SH on glycemic control reported in the present study.   
The SH-associated glycemic deterioration may in part reflect a change in emotional distress and/or 
avoidance behavior among the children/adolescents and/or their parents. Studies have reported that 
episodes of mild hypoglycemia as well as SH is a predictor of fear of hypoglycemia (FOH) in both 
children/adolescents and their parents
23
. FOH causes psychological stress and may affect quality of 










life in the patients as well as their parents
24
. Accordingly, a number of studies have reported that 
FOH is associated with changes in diabetes regulatory behavior with either increased number of 
glucose measurements
25





. However, the relationship between FOH and glycemic 
control in cross sectional studies may not be straightforward
26
 as only some
8,27
 but not all
28
 studies 
report a positive association between FOH and HbA1c, indicating that many factors play a role in 
overall glycemic control. Conversely, the deterioration in glycemic control after SH could be due to 
a general poorer diabetes self-care in the groups with one or more SH episodes. However, we did 
not find differences in SMBG or CGM in these groups compared with the group without SH.  
A subgroup of children and adolescents may be genetically
29
 or physiologically predisposed to an 
increased risk of SH
30
. Diminished counter regulatory response has been shown early after diabetes 
diagnosis
31
, differences in counter regulatory response between patients have been described
32
, and 
a variant in the β-2 receptor gene has been shown to be associated with SH
29
. It is therefore possible 
that risk of SH and subsequent dysregulation belongs to a yet unrecognized genotype predisposing 
to hypoglycemia as well as dysregulation. However, further studies are needed to elucidate this. 
 
Strengths and limitations. The national population-based design with a high data completeness and 
a clear definition of SH is a strength of the present study. However, the DanDiabKids provides only 
annual data on SH and HbA1c, and exact dates of SH episodes are thus not available. It would have 
been optimal to model the trajectory of glycemic control in immediate association with the episodes 
of SH. Nevertheless, the data and the population-based design with a large sample size provide 
solid evidence of a long-term and persisting effect of SH on glycemic control, which is likely to 
also apply to children and adolescents with T1D in other countries.  It is a weakness of the present 
study that we do not have data assessing minor hypoglycemia as they may also impact on diabetes 
behavior and glycemic control. It would also be of interest to investigate the impact of SH on 
glycemic control applying the expanded ISPAD 2018 guidelines not requiring coma or convulsions 
but only severe cognitive impairment and need for external assistance
33
. Nevertheless, we find that 
HbA1c remained elevated for years after an SH episode indicating that the assumed psychological 
and/or behavioral burden, may not be of a transitory but rather of lasting concern. 
 
In conclusion, we have revealed a progressive increase in HbA1c after episodes of SH in children 
and adolescents with T1D. Thus, an acute complication such as SH may translate into increased risk 
of long-term complications if not addressed appropriately. Hopefully, the rapid development of 
improved diabetes treatment technologies including closed-loop systems will reduce the incidence 
of SH further. Nevertheless, special attention to fear of hypoglycemia after an episode of SH should 
be a central and standard part of the routine diabetes outpatient management of children and 
adolescents with T1D.  
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Number of severe hypoglycemia episodes 0 1 2 ≥ 3 
   Number of visits 15543 1676 800 774 
   Sex (% male) 50 52 47 55 
   BMI-SDS 0.72 0.85 0.77 0.89 
   HbA1c (mmol/mol) 63.4 67.6 71.1 70.4 
Treatment      
   Human insulin (%) 9.0 8.3 6.8 6.9 
   Insulin analog (%) 27.4 28.9 36.0 29.1 
   Insulin pump (%) 63.6 62.8 57.2 64.1 
Self-monitored blood glucose     
   ≤2 day (%) 5.3 5.1 6.5 5.8 
   3-5 day (%) 34.4 42.6 48.0 43.2 
   6-9 day (%) 40.9 38.4 35.8 39.8 
   >10 day (%) 13.3 9.8 7.8 5.4 
   Continuous glucose monitoring (%) 6.1 4.0 2.0 5.9 
Table 1. Participant characteristics at annual visits stratified by number of previous episodes of severe 
hypoglycemia (SH). SDS, standard deviation score. BMI-SDS and HbA1c (mean). 
 
Table 2 
SH n Estimate (%) CI P-value 
1 294 1.1  0.0 - 2.6 0.02 
2 115 3.3 1.3 - 5.6 <0.01 
3 55 1.8 -1.0 - 4.7 0.14 
4 15 5.9 1.7 - 10.3 <0.01 
>4 27 5.2 1.0 - 9.7 0.01 
 
Table 2. Percentage increase in HbA1c following episodes of severe hypoglycemia (SH) compared with no 
previous SH episodes   
 












Figure 1: Predicted mean six-year trajectories for three hypothetical groups of patients with diabetes onset 
at six years age, who only differ with respect to the occurrence of SH. Prediction adjusted for age (6-12 
years), gender (female) and duration of diabetes. 
Patient 1: No SH; Patient 2: 1 SH in 2nd year (open arrow); Patient 3: 2 SH in 1st and 4th year (filled 
arrows).   
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